A phase I/II study of NB1011 administered intravenously by continuous infusion in an every second week regimen with open-label continuation in cancers that overexpress the enzyme thymidylate synthase

Trial Profile

A phase I/II study of NB1011 administered intravenously by continuous infusion in an every second week regimen with open-label continuation in cancers that overexpress the enzyme thymidylate synthase

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2012

At a glance

  • Drugs NB 1011 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kiadis
  • Most Recent Events

    • 24 Jan 2008 Status change from recruiting to completed, from clinicaltrials.gov record.
    • 24 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top